Assessment of acute pancreatitis severity via determination of serum levels of hsa‑miR‑126‑5p and IL‑6

Abstract

Early assessment of acute pancreatitis (AP) severity is key to its treatment. The present study aimed to explore the role of microRNAs (miRNAs/miRs) combined with inflammatory factors in determining AP severity. For this, serum pro-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-8 and IL-10)] and miRNAs [ Homo sapiens (hsa)-miR-548d-5p, hsa-miR-126-5p and hsa-miR-130b-5p] were detected in patients with mild AP (MAP), severe AP (SAP) and recurrent AP (RAP). High expression of IL-10, TNF-α, hsa-miR-126-5p, hsa-miR-548d-5p and hsa-miR-130b-5p was able to distinguish SAP from MAP and RAP (P<0.05). Multifactorial binary logistic regression analysis indicated that IL-1/IL-6 combined with hsa-miR-126-5p/hsa-miR-548d-5p had a significant influence on AP and AP severity (P<0.05). Receiver operating characteristic analysis revealed that IL-1 combined with hsa-miR-126-5p [area under the curve (AUC), 0.926; sensitivity, 90.0%; specificity, 86.7%, P<0.001] and IL-6 combined with hsa-miR-126-5p (AUC, 0.952; sensitivity, 93.3%; specificity, 90.0%; P<0.001) were able to better distinguish MAP from SAP than IL-1/IL-6 combined with hsa-miR-548d-5p, lipase, and amylase. IL-1 or IL-6 combined with hsa-miR-548d-5p (AUC, 0.924; sensitivity, 83.3%; specificity, 93.3%; P<0.001) were able to better distinguish SAP from RAP than IL-1/IL-6 combined with hsa-miR-126-5p, lipase, and amylase. IL-1 combined with hsa-miR-126-5p (AUC, 0.926; sensitivity, 90.0%; specificity, 86.7%; P<0.001) and IL-6 combined with hsa-miR-126-5p (AUC, 0.952; sensitivity, 93.3%; specificity, 90.0%; P<0.001) were able to better differentiate between MAP and RAP than IL-1/IL-6 combined with hsa-miR-548d-5p, lipase, and amylase. These results demonstrated that the combined detection of serum IL-6 and hsa-miR-126-5p may be useful for the early prediction of AP classification.

Combined detection of procalcitonin, heparin‐binding protein, and interleukin‐6 is a promising assay to diagnose and predict acute pancreatitis

“…A multicenter trial revealed that at a PCT value of 3.8 ng/ml within 96 h after the onset of symptoms, diagnostic sensitivity and specificity for pancreatic necrosis or death were 93% and 79%, respectively 29 . Some studies have also confirmed the potential value of IL‐6 as a prognostic indicator in SAP 30,31 . However, to the best of our knowledge, to date, only 1 study published in 2020 has reported the use of HBP to predict persistent organ failure in AP patients with a specificity of 74%, a sensitivity of 90%, and an AUC of 0.82 25 .…”

“… 29 Some studies have also confirmed the potential value of IL‐6 as a prognostic indicator in SAP. 30 , 31 However, to the best of our knowledge, to date, only 1 study published in 2020 has reported the use of HBP to predict persistent organ failure in AP patients with a specificity of 74%, a sensitivity of 90%, and an AUC of 0.82. 25 Our study revealed that the concentrations of analyzed biomarkers were all significantly higher in deaths than in survivors, suggesting that elevated levels were important risk factors for the development of AP.…”

Diabetic Bone Marrow Cell Injection Accelerated Acute Pancreatitis Progression

“…In the study, IL-10 production was increased in diabetic BMC when compared with wt BMC (Figure 5 AP [22]. IL-10 is produced by activated T cells such as Treg, Th17, and Th1 cells and macrophages stimulated by bacterial lipopolysaccharides and catecholamines or clearance of apoptotic cells [23].…”

TSPAN1 silencing protects against cerulein‐induced pancreatic acinar cell injury via targeting AGR2

“…The severity of AP is associated with increased serum levels of inflammatory cytokines markers including TNF‐α, IL‐1β, IL‐6, IL‐8, and IL‐10 (Chen et al, 2021). Furthermore, IL‐6 is identified as a significant inflammatory cytokine marker in the development of AP (Ćeranić et al, 2020).…”